Denali Q3 net loss widens to $103.3M; cash at $1.11B after $296M offering

Denali Therapeutics Inc.

2022-Q3 EPS reported -$1.85 revenue$98,180,000

Net loss of $103.3M for Q3 2022 vs. $84.6M in Q3 2021; collaboration revenue fell to $3.6M from $5.3M.
R&D expenses rose to $87.8M (up $16.2M) driven by LRRK2 milestone payment and pipeline progress.
Cash, cash equivalents, and marketable securities totaled $1.11B as of Sep 30, 2022, plus net proceeds of $296.2M from Oct 2022 public offering.
Phase 3 LIGHTHOUSE study of BIIB122 initiated in LRRK2-positive Parkinson's; Phase 2 COMPASS study of DNL310 enrolling in Hunter syndrome.
Interim Phase 1 data for TAK-594/DNL593 showed substantial CSF progranulin increases supporting FTD-GRN Part B dosing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Denali Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $103.3 million.

Period: the third quarter ended September 30, 2022
Net income: net loss of $103.3 million
Result: reported results

Exact text from the filing

Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-22-000143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.